Interview 29 Jan 2018
Meet the CEO of the Other Big Biotech Acquisition Target in 2017
Christian Schetter’s company, Rigontec, was acquired by MSD last year for nearly half a billion euro. How did he and…
Rigontec
- Latest Posts
Best in Biotech 5 Dec 2017
Europe’s Brightest Stars: The 9 Best Biotech Companies of 2017
Tis the season for Glühwein, Tannenbäume, and lights in Berlin, and Labiotech is celebrating with its year-end lists of the…
News and Trends 6 Sep 2017
MSD Offers €464M to Buy German Biotech Fighting Cancer with RNA
MSD is back in the RNA field with the acquisition of Rigontec, a German biotech harnessing RNA interference to make…
News and Trends 3 May 2017
Immuno-oncology Pioneer Enters the Clinic with its RNA-based Therapy
Rigontec has announced the start if its first-in-human Phase I/II study with its pioneering RNA-based candidate, RGT100, in solid tumors…
ADVERTISEMENT
News and Trends 6 Sep 2016
“This 30M Series A will help us bring RNA Therapeutics to Immuno-Oncology”
Rigontec is taking a totally new RNA-based approach to immuno-oncology via the RIG-I receptors. The company extended its Series A…
News and Trends 15 Oct 2014
Recently Launched Company Rigontec already Raised 9,45M Euros against Cancer
Rigontec GmbH, a German privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announced…
